KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Return on Sales (2016 - 2025)

Alnylam Pharmaceuticals' Return on Sales history spans 17 years, with the latest figure at 0.1% for Q4 2025.

  • For Q4 2025, Return on Sales rose 24.0% year-over-year to 0.1%; the TTM value through Dec 2025 reached 0.1%, up 23.0%, while the annual FY2025 figure was 0.08%, 21.0% up from the prior year.
  • Return on Sales reached 0.1% in Q4 2025 per ALNY's latest filing, down from 0.23% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.23% in Q3 2025 to a low of 1.54% in Q3 2022.
  • Average Return on Sales over 5 years is 0.55%, with a median of 0.58% recorded in 2023.
  • Peak YoY movement for Return on Sales: soared 173bps in 2023, then plummeted -47bps in 2025.
  • A 5-year view of Return on Sales shows it stood at 1.0% in 2021, then surged by 38bps to 0.62% in 2022, then skyrocketed by 49bps to 0.31% in 2023, then surged by 55bps to 0.14% in 2024, then surged by 172bps to 0.1% in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Return on Sales are 0.1% (Q4 2025), 0.23% (Q3 2025), and 0.09% (Q2 2025).